- Home
- NBIX
as 12-18-2024 1:40pm EST
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 13.1B | IPO Year: | 1996 |
| Target Price: | $165.00 | AVG Volume (30 days): | 884.4K |
| Analyst Decision: | Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.73 | EPS Growth: | 97.40 |
| 52 Week Low/High: | $110.95 - $157.98 | Next Earning Date: | 02-05-2025 |
| Revenue: | $2,242,800,000 | Revenue Growth: | 25.72% |
| Revenue Growth (this year): | 27.07% | Revenue Growth (next year): | 16.60% |
Stock Insider Trading Activity of Neurocrine Biosciences Inc. (NBIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Onyia Jude | NBIX | Chief Scientific Officer | Nov 29 '24 | Sell | $126.29 | 2,331 | $294,372.67 | 15,449 | |
| Boyer David W. | NBIX | Chief Corp. Affairs Officer | Oct 3 '24 | Sell | $113.66 | 1,295 | $147,189.70 | 377 |
Latest Neurocrine Biosciences Inc. News
NBIX Breaking Stock News: Dive into NBIX Ticker-Specific Updates for Smart Investing
Investor's Business Daily
2 days ago
Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades Drug
Benzinga
2 days ago
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
MT Newswires
2 days ago
Neurocrine Biosciences' Crenessity Approved by FDA for Classic Congenital Adrenal Hyperplasia
Investor's Business Daily
5 days ago
Neurocrine Wins FDA Approval For Genetic Disorder Drug
PR Newswire
5 days ago
Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia
Simply Wall St.
7 days ago
Exploring Three High Growth Tech Stocks In The United States
Argus Research
8 days ago
NBIX: Raising target price to $135.00
Argus Research
15 days ago
NBIX: Lowering target price to $132.00
Compare NBIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NBIX Neurocrine Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.